131,870$
-0,05%
Echtzeit-Aktienkurs Intra-Cellular Therapies Inc.
Bid:
Ask:
Echtzeit-Chart der Intra-Cellular Therapies Inc. Aktie
Börsenkurse Intra-Cellular Therapies Inc.
| gettex | - | - | - | - | 122,500€ | 0,82% |
| USA | - | - | - | - | 131,870$ | -0,05% |
| Lang & Schwarz | - | - | - | - | 122,500€ | 0,00% |
| Nasdaq | - | - | - | - | 131,910$ | -0,01% |
Fundamentaldaten der Intra-Cellular Therapies Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 680,85 Mio. | -74,20 Mio. | -74,68 Mio. | -0,72 | - | - | 20,58 |
| 2023 [USD] | 464,37 Mio. | -139,04 Mio. | -139,67 Mio. | -1,46 | - | - | 27,37 |
| 2022 [USD] | 250,31 Mio. | -256,25 Mio. | -256,26 Mio. | -2,73 | - | - | 49,96 |
| 2021 [USD] | 83,80 Mio. | -284,12 Mio. | -284,13 Mio. | -3,50 | - | - | 128,85 |
| 2020 [USD] | 22,81 Mio. | -226,99 Mio. | -227,01 Mio. | -3,23 | - | - | 465,12 |
| 2019 [USD] | 0,06 Mio. | -147,72 Mio. | -147,72 Mio. | -2,68 | - | - | 120762,44 |
| 2018 [USD] | - | -155,13 Mio. | -155,13 Mio. | -2,84 | - | - | - |
| 2017 [USD] | 0,25 Mio. | -98,83 Mio. | -97,77 Mio. | -2,12 | - | - | 29286,87 |
| 2016 [USD] | 0,33 Mio. | -115,36 Mio. | -116,43 Mio. | -2,69 | - | - | 17263,38 |
| 2015 [USD] | 0,09 Mio. | -104,79 Mio. | -104,79 Mio. | -2,91 | - | - | 62288,92 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Intra-Cellular Therapies Inc. Aktie
Intra-Cellular Therapies (ITI) develop new drugs for neuropsychiatric, neurologic diseases, and other Central Nervous System (CNS) disorders. The company integrates the work of medicinal scientists, pharmacologists, biologists, and clinical development scientists to create novel treatments. ITI's lead product, ITI-007, is a first-in-class 5-HT2A antagonist and dopamine receptor phosphoprotein modulator designed to treat schizophrenia with fewer side effects compared to current antipsychotic drugs. ITI has also developed CNSProfileTM, a technology platform that generates molecular signatures for drug compounds, providing insights into the intracellular actions of CNS drugs. This tool helps in drug discovery and development and is used to study the effects of brain-damaging nerve agents, leading to collaborations on antidotes for chemical warfare agents. Additionally, ITI is exploring new drug candidates for symptoms related to the transition from peri-menopause to post-menopause.